Coherus Biosciences | CHRS - Interest Expense On Debt


Coherus Biosciences reported $2.15M in Interest Expense on Debt for its fiscal quarter ending in March of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 364.15M 18.56M Sep/2025
ALKERMES USD 12.28M 7.63M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 32M Dec/2025
Baxter International USD 58M 14M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Coherus Biosciences USD 2.15M 3.2M Mar/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Fujifilm JPY 1.29B 907M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Merck USD 412M 85M Dec/2025
Myriad Genetics USD 800K 100K Mar/2025
Pacira USD 3.89M 387K Dec/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.35M 311K Dec/2025
Zoetis USD 57M 1000K Dec/2025